Ropinirole (as HCl) 2mg, 4mg, 6mg, 8mg, 12mg; ext-rel tabs. Swallow whole. Initially 2mg once daily for 1–2 weeks, then increase by 2mg/day at ≥1-week intervals up to max 24mg/day (for advanced ...
The Food and Drug Administration (FDA) has approved labeling updates regarding dosage and warnings for Requip (ropinirole; GlaxoSmithKline) tablets. The Food and Drug Administration (FDA) has approved ...
Research Triangle Park, NC (December 15, 2004) – Study results published today in the journal Movement Disorders show that Requipâ(ropinirole HCl) Tablets effectively treats the symptoms of primary ...
May 26, 2005 (Atlanta) — As the result of positive phase 3 trials, ropinirole (Requip) has been approved for the treatment of restless legs syndrome (RLS). The data presented here at the 2005 American ...
Philadelphia, PA (August 1, 2004) – New data published in the August issue of SLEEP shows that patients with primary Restless Legs Syndrome (RLS) and with periodic leg movements during sleep (PLMS), ...
Aug. 24, 2005 — The U.S. Food and Drug Administration (FDA) approved in May revisions to safety labeling to advise that use of ropinirole for the treatment of moderate to severe restless legs syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results